Background: Recent reviews have highlighted the potential use of blood-based methylation biomarkers as diagnostic and prognostic tools of current and future alcohol use and addiction. Due to the substantial overlap that often exists between methylation patterns across different tissues, including blood and brain, blood-based methylation may track methylation changes in brain; however, little work has explored the overlap in alcohol-related methylation in these tissues.
G ROWING EVIDENCE SUGGESTS that epigenetic modifications, which refer to changes in the DNA that do not change the underlying nucleotide sequence, may play a role in alcohol use and addiction (Nieratschker et al., 2013; Robison and Nestler, 2011) . These modifications serve to provide phenotypic plasticity in response to the environment and include closely related processes of DNA methylation, histone modification, and chromatin remodeling. In the case of DNA methylation, a methyl group is attached at the carbon 5 position of a cytosine and is most often, although not exclusively, found in the sequence context of CG. Methylation could be relevant to the mechanisms underlying alcohol consumption and addiction. For example, repeated acute exposure to alcohol leads to chronic cycles of consumption and withdrawal that evoke long-lasting neuroplasticity thought to contribute to abusive consumption, dependence, sensitization, and increased risk for relapse even after years of abstinence (Nestler, 2001 ). These observations suggest lasting cellular and molecular modifications. DNA methylation, being the archetypal cellular information storage mechanism, has been heavily implicated as a chief mechanism for stable activity-dependent transcriptional alterations within the central nervous system (Heyward and Sweatt, 2015) . Drugs of abuse are known to induce epigenetic changes that can persist over time and have lasting effects (Nestler, 2014) , which may explain the observations above.
Recent reviews have highlighted the biomarker potential of blood-based DNA methylation as diagnostic and prognostic tools of current and future alcohol use and addiction (Andersen et al., 2015; Mahnke et al., 2017; Tulisiak et al., 2017) and noted several examples in the extant literature of blood-based methylation alcohol biomarkers (see, e.g. Beach et al., 2015; Heberlein et al., 2015) . These reviews also suggest that blood-based methylation may track methylation changes in brain (Tulisiak et al., 2017) due to the substantial overlap that often exists between methylation patterns across different tissues (Eckhardt et al., 2006) . There is ample evidence supporting partly overlapping methylation profiles between human blood and postmortem brain samples (Davies et al., 2012) as well as correlated drug-induced methylation changes in rodent blood and brain . Studies in humans and rodents of other drugs of abuse show that overlap between brain and blood methylation does occur (Nestler, 2001 (Nestler, , 2014 . However, little work has explored the overlap in alcohol-related methylation in blood and brain. Barker and colleagues (2013) found that alcohol altered methylation in the promoter of Htr3a in a 5-day drinking in the dark mouse model in blood, hippocampus, dorsomedial striatum, and dorsomedial prefrontal cortex, but found no effect in 6 other brain regions. To our knowledge, the study by Barker and colleagues (2013) is the only study to have compared alcohol-related methylation in blood and brain tissue, although that report only analyzed a single gene. Therefore, comprehensive investigations need to be conducted to identify alcohol-related methylation sites in brain whose methylation profile is reflected in blood (Tulisiak et al., 2017) .
Here, we interrogate all 22 million autosomal CpG (cytosine and guanine bonded by a single phosphate group) sites of the mouse methylome for their response to acute ethanol (EtOH) exposure in both blood and brain to identify overlapping methylation in both tissues. For the brain, we chose the striatum because of the established connection between neurobiological and microcircuit changes to this region resulting from alcohol and/or drug addiction (Koob, 2014; Koob and Volkow, 2016) . Simultaneous analysis of the blood and brain methylomes will determine the degree of methylation overlap between these tissues and establish a set of methylation sites in blood that can potentially be used as proxy for brain in alcohol methylation studies. To our knowledge, this is the first study to explore the effect of alcohol on DNA methylation on a methylome-wide scale in rodents and consider the overlap across tissues on such a scale.
MATERIALS AND METHODS

Ethics Statement
All procedures were approved by Virginia Commonwealth University Institutional Animal Care and Use Committee under protocol number AM10332 and followed the NIH Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, 1996) .
Animals
Forty male DBA2/J (D2) mice from Jackson Laboratories (Bar Harbor, ME) were purchased at 10 to 13 weeks of age and grouphoused 4/cage. Mice were maintained in a temperature-controlled room (23°C AE 1) with 12-hour light/dark cycles and free access to standard chow (Harlan Teklad #7912; Madison, WI) and water. Cages and bedding (Harlan Sani-chips, #7090A) were changed weekly. All tests were carried out between 0900 and 1200 hours. All mice were allowed to habituate to the animal facility for at least 1 week prior to testing.
Drugs
All injections were administered intraperitoneally (i.p.). Saline solutions were prepared by dissolving NaCl in sterile water to a concentration of 0.9% weight per volume. EtOH solutions were prepared from 200-proof absolute anhydrous EtOH (Pharmco-Aaper brand, Brookfield, CT). EtOH was administered at 20% v/v in 0.9% saline.
Behavioral Testing and Material Collection
Animals received 1 of 2 possible i.p. injections: saline or 2.0 g/kg EtOH. They were then returned to their home cages, and 4 hours following injection, they were killed by cervical dislocation followed by decapitation and collection of trunk blood. Brains were then extracted, and the striatum was excised as described previously (Kerns et al., 2005) . The excised region was placed in an individual tube, flash-frozen in liquid nitrogen, and stored at À80°C. Genomic DNA was extracted using the Gentra Puregene Blood/Tissue Kit (Qiagen, Valencia, CA) following the vendor's instructions.
Methylation Assay
Our approach (Aberg et al., 2012; Chan et al., 2017) to assay the entire CpG methylome has been described previously. Briefly, genomic DNA was fragmented with ultrasonication (Covaris TM E220; Woburn, MA) to a median length of~150 bp; we used MethylMiner (Invitrogen, Carlsbad, CA) which employs methyl-CpG binding domain (MBD) protein-based enrichment of the methylated DNA fraction, followed by single-end sequencing (50-bp reads) on the SOLiD platform (Life Technologies, Carlsbad, CA). We eluted the captured methylation fractions with 0.5 NaCl to increase the relative number of fragments from CpG poor regions (Aberg et al., 2012) , which otherwise would not be as well covered. Compared to other MBD kits, this protocol has a favorable noise-to-signal ratio and coverage of the methylome (Aberg et al., 2015) .
Alignment and Quality Control
Reads were aligned to the D2-specific reference genome (Wang et al., 2010) using Cushaw3 (Liu et al., 2012 ). An overview of the quality control (QC) procedures can be found elsewhere (Aberg et al., 2012) . We obtained an average of 32.4 million reads per sample (SD = 12.6 million), of which on average 77.9% (SD = 7.7) aligned. After alignment, reads were further filtered on quality score and duplicate reads were removed.
In studies aimed at calling single nucleotide polymorphisms (SNPs) or estimating the absolute percentage of methylation at specific bases (e.g., Whole Genome Bisilfite Sequencing [WGBS] ), the total number of reads covering each base is a critical determinant of the precision of the methylation estimates. For example, if a base is sequenced at 109 coverage in WGBS, its methylation level can be estimated in only 10% increments since methylation status at a CpG is binary for any given DNA molecule and methylation is estimated as the number of reads/molecule (0. . .10), with methylated CpGs divided by the total number of reads. In enrichmentbased sequencing, coverage itself is the measured variable, where precision is determined by total number of reads (or more precisely fragments) covering a CpG or what we call CpG score. The higher the level methylation is at a given locus (i.e., the percentage of cells in which that locus is methylated), the more likely it is to be captured by MBD protein pulldown. Thus, loci with higher methylation levels will obtain more reads than loci with low methylation levels. At the other extreme, loci that are nonmethylated in all cells are not captured during MBD pulldown and are not represented in the sequencing library. The lack of coverage for these nonmethylated loci is therefore expected and is not a consequence of poor sequencing performance. For this approach to distinguish between methylated loci versus nonmethylated loci, it is critical that fragments with methylated sites are pulled down (e.g., if a methylated site is not pulled down, then we might erroneously conclude that it is not methylated). Thus, rather than the average number of reads covering CpGs, the critical QC parameter is the ratio of the average CpG score (van den to the average score of sites that are not CpGs (labeled as non-CpGs) and, therefore, cannot be methylated. Higher levels of this ratio indicate higher enrichment efficiency. Note that because not all CpGs are methylated, this ratio is an underestimate of the enrichment efficiency. The opposite of this ratio, average non-CpG score/average CpG score, is a measure of the noise level with lower values indicating less noise.
The number of reads is important in the sense that if too few reads are sequenced there may not be enough to cover each CpG. Other authors have suggested that 30 to 60 million reads per human sample are sufficient for high-quality methylation profiles (Bock et al., 2010; Chavez et al., 2010) . Here, we study mice. Given that the mouse genome is~15% smaller than the human genome (Guenet, 2005) , the equivalent need is 25.5 to 51 million reads per murine sample. In the present study, we obtained an average of 32.4 million reads per sample, which is within the suggested range.
Akin to genomewide association studies where SNPs are filtered based on minor allele frequency, the last step of the QC procedure involved removing sites that were rarely methylated (CpG score <0.3). The main purpose for this filtering is because these sites lack biological variation and to avoid statistical problems caused by sparse data. This resulted in a total of 13,352,028 CpGs available for the blood and brain methylome-wide association studies (MWASs). Table S1 shows the distribution of CpGs in the MWAS by genomic feature.
In this study, we observed an average CpG score (van den Oord et al., 2013) of 2.58 (SD = 7.59), with an average CpG-to-non-CpG score ratio of 70.4 (SD = 42.9) and average non-CpG-to-CpG score ratio (Shabalin et al., 2018) of 0.024 (SD = 0.020). Thus, the average CpG signal is strong, enrichment efficiency is high, and the background noise level is low, allowing for detection of differently methylated sites. Data are available from the Dryad Digital Repository: https://doi.org/10.5061/dryad.372c76c.
Statistical Analyses
Methylation Association Testing. We regressed the methylation measurement of individual CpGs on treatment status (EtOH or saline) to determine the effect of EtOH on the methylome using RaM-WAS (Shabalin et al., 2018) . Potential technical batch effects were controlled for by including them a covariate in the regression analysis. According to a stringent Bonferroni correction, p < 5 9 10 À8 were considered statistically significant. p < 1 9 10 À5 were considered suggestive. Separate MWASs were conducted for blood and brain, respectively. Pathway Analyses. We used the Gene Set Knowledgebase (GSKB; Bares and Ge, 2015) to perform pathway analyses based on Biocarta, MouseCyc, NetPath, PANTHER, and INOH. Genes located within AE20 kb from a CpG with p < 1 9 10 À5 were included in the pathway analysis. For each of 892 reference pathways present in GSKB, incorporating 4,463 known genes, a hypergeometric test was performed to study whether the overlap between the top MWAS genes and those present in each reference pathway was higher than expected by chance. Only pathways that contained at least 2 genes from our MWAS results were retained. A p-value threshold of 0.05 was used to determine significance.
Enrichment Testing for Genomic Features. To examine whether the top results from the blood and brain MWASs were enriched for specific genomic features, we used the R package shiftR. To perform these tests, shiftR uses circular permutations (Cabrera et al., 2012) by shifting the mapping of the 2 data sets by a single random integer in each permutation. This approach generates the empirical test statistic distribution under the null hypothesis while preserving the correlational structure of the data. We used 1 million permutations for each test. Multiple thresholds (i.e., for our analyses, we used the top 1, 5, and 10%) were used to define "top" findings for the blood and brain MWAS. To account for this "multiple testing," the same thresholds are used in the permutations where the test statistic distribution under the null hypothesis is generated from the most significant combination of thresholds. For bivariate data sets, such as the genomic features, the presence versus absence of a feature defined the "top." The genomic features investigated include overlap with genic, exonic, intronic, 3 0 UTR, and 5 0 UTR regions as defined by RefSeq (Pruitt et al., 2014) , gene promoters (within 8 kb of a gene transcription start site), CpG Islands, CpG Shores (2-kb flanking CpG Islands), high areas of conservation across eutherian mammals, and noncoding RNA (functional RNA molecule that is not translated into a protein).
Blood and Brain Overlap. We also used enrichment testing in shiftR to investigate whether top findings from the blood MWAS occur more frequently among the top findings of the brain MWAS (i.e., are enriched) than what is expected by chance. For this test, the 2 data sets were first mapped to each other based on chromosomal location where 20-kb flanks were allowed in the blood MWAS to account for the fact that association signals may involve a region rather than a single base position. After this step, enrichment testing proceeded as described in the previous section.
After enrichment testing, we further investigated overlapping top results by performing pathway analyses as described in the previous section. For these pathway analyses, we took a conservative approach by including only overlapping CpGs that had the same direction of effect in both tissues and a p < 0.01 in both sets of results to avoid an extreme p-value in 1 set of findings dominating the results.
RESULTS
Methylome-Wide Association Study
Two CpGs, 1 in each tissue, reached statistical significance (p < 5 9 10 À8 ). The CpGs were located in the introns of Ttc39b and Espnl in brain and blood, respectively. In addition, 7 CpGs in brain and 8 in blood were significant at the p < 1 9 10 À7 level (Table 1 ). For both brain and blood, these top findings tended to be located within gene boundaries and evolutionarily conserved regions. When suggestive sites were considered (p < 1 9 10 À7 ), we identified 40 and 84
CpGs in brain and blood, respectively (see Tables S2 and S3 for an annotated list of all results with p < 1 9 10 À5 in brain and blood, respectively). Pathway analyses were conducted on sites with p < 1 9 10 À5 located in genes, which corresponded to 39 and 77 genes being used as input for the pathway analyses in brain and blood, respectively. In brain, pathway analyses related to responses to extracellular stimuli including CXCR4, Wnt, IL-7, and G-protein signaling (Table 2) . Evidence for the importance of glutamate receptor pathways was found in both blood and brain.
Characteristics of CpGs Associated with Acute EtOH Exposure
Given the observation that many of the top findings in both tissues were located in genes, we tested whether the top findings from the brain and blood MWASs were enriched for other genomic features. Results show (Fig. 1 ) that top MWAS findings for brain tended to be located in introns and exons of genes and in evolutionarily conserved regions as indicated by the points for these features exceeding the significant threshold (vertical dashed line). For blood, the top MWAS findings were likely to be in introns and exons of genes, gene promoters, and CpG Islands and shores.
Overlap in CpGs Between Brain and Blood Results
The results of our enrichment testing indicated that there was a significant enrichment of top 10% blood MWAS findings among the top 10% brain MWAS Chromosome ("Chr"), "Coord" is the coordinate of the CpG. "Gene" indicates which gene the CpG falls in the boundary of. "Feature" describes attributes overlapping the CpG. "Intron" designates overlap with RefSeq genes. "Conserved" indicates CpG lies with an evolutionarily conserved region; "Bidirectional promoter" indicates a CpG lies in a regulatory region that fall between pairs of genes, where the 5 0 ends of the genes are positioned in close proximity to one another. MWAS, methylome-wide association study. Total is the total number of genes in the pathway; Gene No. is the number of genes in the pathway with p < 1 9 10 À05 in the MWAS. findings (multiple testing corrected permutation p = 0.021). This overlap corresponded to 370 sites with p < 0.01 in both MWASs and with the same direction of effect. The pathways of the 148 implicated genes overlapping between tissues (Table 3) were central to mitogenactivated protein kinase (MAPK) signaling and those upstream such as the Ras pathway, TNF/stress-related signaling, and growth factor signaling. Additional pathways implicate glutamatergic and adrenergic signaling.
DISCUSSION
By screening the 22 million CpGs in the mouse methylome, we identified some methylation changes in brain and blood after acute EtOH administration. Several of the changes were located in genes or regions that have previously been associated with alcohol in humans. Espnl was found to be associated with initial alcohol sensitivity and acute withdrawal in a linkage study (Kuo et al., 2006) . A variant in Utp20 was found to convey risk for age of onset of alcohol dependence (Kapoor et al., 2014) . To further explore the potential overlap between our methylation results and human genetics results, we examined the 15 genomewide significant loci reported in recent human alcohol genomewide association studies Clarke et al., 2017; Jorgenson et al., 2017; Mbarek et al., 2015; Schumann et al., 2016) , 13 of which were located in genes with direct homologues in mice, and found that none of these genes were among the top tissue-specific results (Table 1 ). Enrichment testing revealed that top findings from both the brain and blood MWASs tended to be located in intronic and exonic regions for both the brain and blood MWASs. The blood MWAS findings were also significantly enriched for CpG Islands. The enrichment findings are consistent with previous studies demonstrating that disease and environmental exposure-related methylation is likely to occur outside of gene promoters and CpG Islands (Irizarry et al., 2009 ).
Pathway analyses based on the results of the individual MWASs showed multiple significant results in brain, implicating several related pathways involved in the acute response to EtOH. Many of these pathways have established roles in neuroadaptation following physical or chemical insults. For example, genes within the CXCR4 pathway are overtargeted by miRNAs in the prefrontal cortex of human alcoholics (Lewohl et al., 2011) . In adult rats, CXCR4 is expressed in striatal interneurons and may modulate cholinergic and dopaminergic signaling (Banisadr et al., 2002) . The proinflammatory IL-7 pathway contributes to reactive gliosis and can induce neural progenitor cell differentiation (Moors et al., 2009 ). Thus, altered methylation of genes within the CXCR4 and IL-7 pathways may highlight an effect of acute EtOH on neuroinflammation and neuroplasticity.
Members of the Wnt signaling pathway (and the related presenilin pathway) were also heavily featured in our brain pathway results. The Wnt family of morphogens are key regulators of neural maturation and are essential for maintenance of dopaminergic neurons in the midbrain (Arenas, 2014) . Acute EtOH exposure suppresses expression of WNT3A, WNT5A, and the frizzled coreceptor LRP6 in human neural stem cells (Vangipuram and Lyman, 2012) . Changes in DNA methylation among pathway members may facilitate EtOH-induced suppression in Wnt signaling.
The remaining significant pathways in brain revolved around members involved with glutamatergic, calcium, and G-protein signaling. Pharmacological inhibition of the N-type voltage-gated calcium channel Ca v 2.2 (Cacna1b) results in reduced EtOH intoxication, reinforcement, and reward in mice (Newton and Messing, 2009 ). Kcnj5, the G bcactivated inward rectifying potassium channel 4 (GIRK4), contains a binding site for and is activated by EtOH (Aryal et al., 2009) , and is necessary for EtOH-induced conditioned place preference in mice (Tipps et al., 2016) . Knockout of calcium-dependent protein kinase C epsilon (Prkce), commonly featured in the enriched pathways, modulates EtOH consumption and sensitivity in mice (Choi et al., 2002) . Total is the total number of genes in the pathway; Gene No. is the number of genes in the pathway with p < 0.01 and the same direction of effect in both the brain and blood methylome-wide association study.
Within the brain, the NMDA and AMPA glutamate receptors are the highest affinity sites of EtOH-induced inhibition (Nagy, 2008) . Furthermore, the gene promoters of the mGluRs have been shown to be more highly methylated in alcoholic patients (Meyers et al., 2015) .
We also identified 1 significant pathway in blood implicating glutamatergic signaling. Of note, glutamate receptor ionotropic kainate 1 encoded by the pathway member Grik1 is also potently inhibited by EtOH (Valenzuela and Cardoso, 1999) . Additionally, genetic polymorphisms in GRIK1 are contributors to alcohol dependence risk (Kranzler et al., 2009 ) and predictors of treatment outcomes (Kranzler and Edenberg, 2010) . While it is unclear whether the observed changes in methylation in glutamatergic pathways in blood are due to the inhibitory effect of EtOH, it remains plausible as many glutamate receptors are expressed in the periphery (Gill and Pulido, 2001 ). More importantly, from a biomarker perspective, affected biochemical pathways in the brain are also detected in blood following acute EtOH exposure.
Extending our pathway analyses beyond individual tissues, we further tested for enrichment between brain and blood, revealing a significant overlap among the top MWAS findings in the 2 tissues. Pathway analyses of the overlap between tissues indicated MAPK, growth factor, and G-protein signaling pathways. The predominant members of the enriched pathways are found at the MAP2K (MAPKK/ MEK1/MEK2) level, upstream of p38/ERK1/ERK2. Treatment with MAP2K or p38 inhibitors leads to changes in EtOH consumption in mice trained to self-administer (Agoglia et al., 2015) . This analysis also suggests G-proteincoupled receptor signaling via a-adrenergic receptors may contribute to the acute effects of EtOH, evidenced by the number of G aq and Ca
2+
-dependent members implicated (Plcb4, Plce1, Prkar1b, Prkg1, Prkca, Prkce). Extensively studied because of its involvement in the physical and motivational components of addiction (Walker et al., 2008) , adrenergic receptors have been suggested as potential targets for alcohol dependence pharmacotherapies (Rasmussen et al., 2009) . Indeed, preliminary trials with the a-adrenergic antagonist prazosin have shown promising results for treatment for alcohol dependence and craving (Simpson et al., 2018) .
Our results showing overlapping methylation signals in blood and brain from the same animal suggests that alcoholrelated methylation in blood partly, but not fully, mirrors changes that occur in brain tissue. While our finding was from a model system, it is possible that some of these findings would extend to humans. This finding has important potential implications for the clinical application of blood biomarkers as it provides some evidence that methylation in blood might be able to be used as a proxy tissue to detect some processes that occur in brain as a result of EtOH; however, our findings require further validation and replication, preferably using a different method to measure methylation.
One form of validation would be to examine the overlapping genes for differential gene expression in brain tissue by comparing acute EtOH-exposed to saline-exposed mice. Using the results from a gene expression study where mice underwent a similar protocol to the one used in this study (Wolen et al., 2012) , we annotated our overlapping gene list to indicate whether a gene was differentially expressed between acute EtOH-and saline-exposed mice (Table S4 ). In total, there were 23 genes from the overlapping gene list that were expressed in either the prefrontal cortex, nucleus accumbens, or ventral midbrain. However, the results reflect differential gene expression that occurred at the time of death of the mice and may not capture any differences that occurred before death. As such, there may be more differentially expressed genes than what is listed in Table S4 . It should also be noted that not all methylation sites have an impact on expression of the closest gene. Many methylation sites are relatively far from the genes they influence and have other more complex regulatory effects than a negative correlation with the closest gene.
The MWASs performed here used DNA from bulk tissue (i.e., blood and brain). However, both of these tissues contain multiple cell types. While we did not consider the effect of acute EtOH administration in the different cell types, we recognize that knowing what cell type caused an association is key for further understanding the biological implications of findings and can be critical for designing proper (functional) follow-up studies. To further this aim, we have compiled expression levels for each of the overlapping genes from publicly available, cell-type-specific gene expression mouse databases (Table S5) . For blood, we used the "Mouse normal hematopoietic system" track from BloodSpot (Bagger et al., 2016) , and for brain, we utilized the database established by Zhang and colleagues (2014) .
There are several natural extensions to the work presented here. First, our study focused on first contact with alcohol. However, methylation patterns may be different after repeated exposures or during other stages of addiction, such as the development of dependence after chronic administration, withdrawal when EtOH is discontinued, and, after extended abstinence, the possibility of a persistent biological memory of past alcohol exposure that may prime mice to the effects of renewed alcohol exposure. Second, the mice in our studies were administered EtOH through i.p. injections. Selfadministration models of EtOH may yield different methylation patterns as methylation studies using forced administration models may pick up on the negative reinforcing effects of EtOH. Last, the landscape of the brain methylome is complex. For example, in the vast majority of mammalian somatic tissues methylation involves the addition of a methyl group to CG dinucleotides (Lister et al., 2009 ). However, the brain methylome contains other forms of methylation that are rare or absent in other tissues. This includes methylation outside the CG context and hydroxymethylation. Future work should assess the impact of EtOH on these additional methylation forms.
In summary, our results show that there are some methylation changes occurring in both brain and blood after acute EtOH administration. By comparing brain and blood from the same animal, we have provided provisional evidence that alcohol-related methylation in blood at least partly reflects methylation occurring in brain by demonstrating an enrichment of top brain findings among the top blood findings. Pathway analyses suggest that the overlapping genes may tag alcohol-related processes. These findings provide preliminary evidence that blood-based methylation sites might be able to be used as proxy sites for brain when developing biomarkers for alcohol-related outcomes but require further validation and replication. Williams R (2010) 
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